Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Undergraduate: Mobility, musculoskeletal health and arthritis - ICS

University of Toronto

$5,000.00

Screening for V-ATPase inhibitors to identify therapeutics to prevent bone loss in inflammatory arthritis.

FY 2013-14

Summary
Current therapies to prevent pathological bone loss resulting from arthritis and osteoporosis lack effectiveness and have serious side effects. Osteoclasts normally dissolve bone by pumping acid onto the bone surface as part of a continuous renewal process, but this is accelerated in pathological bone loss. V-ATPase molecules are the acid pumps of osteoclasts, and inhibiting V-ATPase activity prevents bone loss in the laboratory, but compounds that reduce V-ATPase function also interfere with their essential activity in other parts of the body and are toxic. V-ATPases consist of many subunits, some having different isoforms. The distribution of isoforms varies, depending on the V-ATPase's final destination. One such isoform, a3, is found mainly in the osteoclast acid pump and interacts with two other components found mainly in osteoclasts, B2 and d2. Our goal is to use the a3/B2 a3/d2 interactions as key components in a screen to identify compounds that disrupt this interaction and thereby potentially 'knock out' the osteoclast V-ATPase without affecting other essential V-ATPases. We have done a pilot scale screen of fifty thousand drug-like synthetic chemicals, among which we have identified a few 'hits'. We propose here to have James Kim perform secondary cell-based screening, towards the development of antiresorptive drugs that would only affect the osteoclast V-ATPase involved in pathological bone loss in inflammatory arthritis and osteoporosis.
Program
Undergraduate: Mobility, musculoskeletal health and arthritis - ICS
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
303305
Name
Kim Joo Wan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Undergraduate: Mobility, musculoskeletal health & arthritis - IMHA
Projecttitle
Screening for V-ATPase inhibitors to identify therapeutics to prevent bone loss in inflammatory arthritis.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$5,000
Cihrequipment2
$0
Programname2
Undergraduate: Mobility, musculoskeletal health and arthritis - ICS
Keyworddelim
Arthritis; Bone; Bone Loss; Bone Resorption; Osteoporosis; V-Atpases
Abstract
Current therapies to prevent pathological bone loss resulting from arthritis and osteoporosis lack effectiveness and have serious side effects. Osteoclasts normally dissolve bone by pumping acid onto the bone surface as part of a continuous renewal process, but this is accelerated in pathological bone loss. V-ATPase molecules are the acid pumps of osteoclasts, and inhibiting V-ATPase activity prevents bone loss in the laboratory, but compounds that reduce V-ATPase function also interfere with their essential activity in other parts of the body and are toxic. V-ATPases consist of many subunits, some having different isoforms. The distribution of isoforms varies, depending on the V-ATPase's final destination. One such isoform, a3, is found mainly in the osteoclast acid pump and interacts with two other components found mainly in osteoclasts, B2 and d2. Our goal is to use the a3/B2 a3/d2 interactions as key components in a screen to identify compounds that disrupt this interaction and thereby potentially 'knock out' the osteoclast V-ATPase without affecting other essential V-ATPases. We have done a pilot scale screen of fifty thousand drug-like synthetic chemicals, among which we have identified a few 'hits'. We propose here to have James Kim perform secondary cell-based screening, towards the development of antiresorptive drugs that would only affect the osteoclast V-ATPase involved in pathological bone loss in inflammatory arthritis and osteoporosis.
Competitiondate
201401
Approvedterm2
0 yr 3 mths
Pinamesdelim
Kim, Joo Wan
Approvedterm
0 an 3 mois
Cihrcontribution2
~ $5,000~ $0~